CONDITION

Refractory anemia

Refractory anemia is an older term for a bone marrow condition that causes ongoing low red blood cell levels.

WHAT IT IS
Older term for a low-risk myelodysplastic condition

BODY SYSTEM
Blood and bone marrow

MAIN SYMPTOMS
Fatigue, breathlessness, pale skin, dizziness

WHAT CAUSES IT
Acquired bone marrow cell changes, often unknown

HOW IT IS DIAGNOSED
Blood counts and bone marrow examination

MAIN TREATMENT
Supportive care, targeted medicines, sometimes stem cell transplant

CAN IT BE CURED?
Sometimes - stem cell transplant can cure

IS IT AN EMERGENCY?
Sometimes - severe breathlessness, chest pain, or uncontrolled bleeding

LONG-TERM OUTLOOK
Often slow-moving, but some cases progress

Overview

Refractory anemia is an older medical term. It was mainly used for a type of myelodysplastic syndrome , now often called a myelodysplastic neoplasm , or MDS. MDS affects the bone marrow, the soft tissue inside bones where blood cells are made.

In refractory anemia, the marrow does not make enough healthy red blood cells. Red blood cells carry oxygen around the body. A shortage is called anemia.

"Refractory" means that the anemia continues despite usual approaches or is caused by a lasting marrow problem. It does not automatically mean that every treatment will fail. It also does not mean that the anemia is caused by low iron.

Modern classification systems no longer use refractory anemia as a main diagnosis. They

classify MDS using blood counts, bone marrow appearance, chromosome findings, gene changes, and the number of immature cells called blasts. If this term appears in an older record, a blood specialist can explain which current MDS category best matches it.

The condition matters because anemia can affect energy, breathing, concentration, and physical activity. Some people remain stable for years. Others develop lower white blood cell or platelet counts, or progress to a faster-growing marrow condition.

Symptoms

Symptoms usually come from having too few healthy red blood cells. Mild anemia may be found on a routine blood test before you notice anything unusual.

Possible symptoms include:

Some people with MDS also have low white blood cells or platelets. Low white blood cells can increase the risk of infection. Low platelets can cause easy bruising, nosebleeds, bleeding gums, or small red-purple spots under the skin.

These symptoms have many possible causes. Having them does not mean that you have refractory anemia or MDS.

- Tiredness, weakness, or reduced stamina
- Shortness of breath, especially during activity
- Pale skin
- Dizziness, headaches, or difficulty concentrating
- A fast or noticeable heartbeat
- Chest discomfort in people whose heart is under strain

Causes and risk factors

Refractory anemia associated with MDS develops when blood-forming stem cells in the bone marrow acquire abnormal changes. These cells then produce blood cells that may be misshapen, short-lived, or unable to mature normally.

The exact cause is often not found. Most cases are acquired during life rather than inherited from a parent.

Factors linked with a higher chance of developing MDS include:

A previous cancer treatment does not mean that MDS will develop. When MDS follows

chemotherapy or radiation, it is called therapy-related MDS.

Refractory anemia should not be confused with common anemia caused by iron, vitamin B12, or folate deficiency. It can sometimes occur alongside these problems, so testing for treatable causes remains important.

- Older age
- Previous treatment with certain chemotherapy medicines or radiation
- Significant exposure to benzene or some other industrial chemicals
- Smoking
- Rare inherited conditions that affect bone marrow or DNA repair

Diagnosis

A complete blood count measures red blood cells, white blood cells, platelets, and hemoglobin. Hemoglobin is the oxygen-carrying protein in red blood cells. The red cells may also be larger than usual.

Blood counts alone do not usually confirm MDS. Similar results can occur with vitamin deficiencies, bleeding, kidney problems, inflammation, infections, medicines, alcohol use, and other marrow conditions.

Testing may include:

During a bone marrow aspiration, liquid marrow is removed through a needle. A biopsy removes a small core of marrow tissue. The samples are usually taken from the back of the hip bone using local anesthetic.

A laboratory specialist checks how the cells look and counts blasts. Chromosome testing, also called cytogenetic testing, looks for missing, extra, or rearranged chromosome material. Molecular testing looks for gene changes linked with MDS.

The results help confirm the diagnosis, place it in a modern category, and estimate its risk. Risk scoring considers factors such as blood counts, blasts, chromosome findings, and gene changes. An old label of refractory anemia does not provide enough information by itself to predict the course.

- Repeat blood counts to show whether the problem continues
- A blood smear, which examines blood cells under a microscope
- Iron, vitamin B12, and folate tests

- Kidney, liver, thyroid, and inflammation tests when appropriate
- A bone marrow aspiration and biopsy
- Chromosome and gene testing on blood or marrow cells

Treatment and management

Treatment is based on the current diagnosis, symptoms, blood counts, overall risk, general health, and personal priorities. Some people with stable counts and few symptoms do not need immediate treatment. They have regular blood tests and follow-up instead.

Supportive treatment aims to reduce symptoms and complications. It may include red blood cell transfusions when anemia is severe or troublesome. Transfusions can improve symptoms, but their effect is temporary.

Medicines that encourage red blood cell production may help selected people. Other medicines may be considered when testing finds features such as ring sideroblasts, an SF3B1 gene change, or a deletion involving part of chromosome 5. These treatments are not suitable for every MDS category.

Medicines that change how abnormal marrow cells behave may be used if counts worsen or the condition has higher-risk features. Treatment decisions balance possible benefit against side effects and the burden of clinic visits or monitoring.

People receiving many transfusions can accumulate excess iron because the body has no easy way to remove it. Iron-removing treatment may be considered for selected people after reviewing their transfusion history, expected course, and other health conditions.

An allogeneic stem cell transplant replaces abnormal marrow-forming cells with cells from a donor. It is the only treatment with established curative potential, but it can cause serious complications. Age alone does not decide eligibility; general health, MDS risk, donor options, and personal goals are also important.

Do not start iron supplements simply because you have anemia. Iron helps only when iron deficiency is present, and unnecessary iron can be harmful.

Complications

Ongoing anemia can reduce physical function and quality of life. Severe anemia may place extra strain on the heart, especially if you already have heart or lung problems.

If other blood counts fall, complications can include infections or bleeding. Repeated

transfusions can lead to iron overload and, less commonly, immune reactions that make matching future blood more difficult.

Some MDS conditions progress to acute myeloid leukemia, a faster-growing blood cancer. The chance is not the same for everyone. It is estimated from the current MDS category, marrow blast count, chromosome or gene findings, and changes in blood counts over time.

Prevention

Most cases cannot be prevented because the cell changes often arise without a clear cause.

Avoiding tobacco smoke and unnecessary exposure to benzene or other marrow-damaging chemicals is sensible, but it cannot guarantee prevention. Workplace safety procedures should be followed where chemical exposure is possible.

Cancer treatments can sometimes damage bone marrow, but they may also be essential. Do not avoid, delay, or stop chemotherapy or radiation because of this risk without discussing the benefits and risks with your cancer team.

Families with several cases of marrow failure, MDS, or leukemia at unusually young ages may be offered genetic assessment. Most people with MDS do not have an inherited condition.

Living with it and what to expect

The course may be slow and stable, particularly when blasts are low and chromosome or gene findings suggest lower risk. Some people need only monitoring for a period of time. Others gradually require medicines or transfusions as anemia becomes more noticeable.

Follow-up commonly includes blood counts and a review of symptoms. A repeat bone marrow examination may be considered if counts change, new symptoms develop, or treatment decisions require updated information.

Energy levels can rise and fall with the hemoglobin level. Planning demanding activities for times when you have more energy, taking rest breaks, and staying active within comfortable limits may help. Report a clear decline rather than assuming it is an unavoidable part of the condition.

Keep an up-to-date list of transfusions, treatments, and test results. Tell the healthcare team about new medicines or supplements because some can affect blood counts or interact with treatment.

Many people continue everyday activities, work, travel, and relationships, although

appointments or fatigue may require adjustments. The outlook cannot be predicted from the words "refractory anemia" alone. Modern test results and how the blood counts change over time provide more useful information.

When to get medical help

Arrange routine medical follow-up if you develop increasing fatigue, reduced exercise tolerance, more bruising, repeated infections, or a gradual change in breathlessness. These symptoms may mean that blood counts need checking, but they are not always caused by MDS.

Seek prompt same-day medical advice for:

Seek emergency help for severe difficulty breathing, chest pain, fainting, confusion, vomiting blood, heavy uncontrolled bleeding, or symptoms of a stroke such as sudden weakness or trouble speaking.

- Fever or signs of infection, especially with a known low white cell count
- Bleeding that does not stop with firm pressure
- Black stools, blood in urine, or repeated nosebleeds
- Rapidly worsening weakness, dizziness, or breathlessness

Common questions

Is refractory anemia the same as iron-deficiency anemia?

No. Iron-deficiency anemia happens when the body lacks enough iron. Refractory anemia usually refers to poor blood cell production caused by an MDS-related marrow problem. Iron treatment will not correct it unless iron deficiency is also present.

Does "refractory" mean there is no treatment?

No. The term means that the anemia is persistent or does not respond as expected to simple treatment. Monitoring, transfusions, blood cell growth medicines, targeted treatments, and stem cell transplantation may still be options.

Is refractory anemia cancer?

When the term refers to MDS, it is part of a group now described as myeloid neoplasms, which are blood cancers involving bone marrow cells. Lower-risk MDS can behave very differently from fast-growing cancers and may remain stable for a long time.

Can refractory anemia turn into leukemia?

Some MDS conditions progress to acute myeloid leukemia, but many do not. The likelihood is assessed using marrow blasts, blood counts, chromosome findings, gene changes, and how the condition behaves over time.

Can diet improve refractory anemia?

A balanced diet supports general health but cannot correct abnormal marrow cells. Iron, folate, or vitamin B12 helps only if testing confirms a deficiency. Ask before taking supplements because unnecessary iron can build up in the body.

How long can someone live with refractory anemia?

There is no reliable single answer. Some lower-risk cases remain stable for years, while higher-risk findings can lead to a shorter course or progression. An old diagnosis name is not enough to estimate outlook; current marrow, chromosome, gene, and blood count results are needed.

Sources

- National Cancer Institute. Myelodysplastic Syndromes Treatment (PDQ®)-Patient Version
- National Cancer Institute. Myelodysplastic Syndromes Treatment (PDQ®)-Health Professional Version
- Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia . 2022;36:1703-1719
- Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias. Blood . 2022;140:1200-1228
- Garcia-Manero G. Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management. American Journal of Hematology . 2023
- NHS. Myelodysplastic syndrome